|
Hutchmed China Ltd on Monday said its combination therapy for a specific form of advanced lung cancer significantly delayed disease progression compared to chemotherapy, based on phase III trial data presented at a major oncology conference. The Hong Kong-based developer of treatments for cancer and immunological diseases said results from the China-based Sachi study showed that patients given a combination of savolitinib and AstraZeneca PLC’s osimertinib achieved a median progression-free survival of 8.2 months. That compares to 4.5 months for patients receiving standard chemotherapy. The trial involved patients with EGFR mutation-positive non-small cell lung cancer and MET amplification, whose disease had progressed after first-line EGFR inhibitor treatment. According to Hutchmed, the all-oral combination showed a 58% objective response rate, versus 34% for chemotherapy, and offered a favourable safety profile with no new adverse signals. The combination also more than doubled the median duration of response to 8.4 months. Hutchmed said the China National Medical Products Administration has accepted and granted priority review to a new drug application for the therapy. ‘The results from the Sachi phase III study represent a significant advancement,’ said Professor Shun Lu, the study’s lead investigator. ‘This novel, chemotherapy-free combination offers a convenient and well-tolerated treatment option that addresses critical unmet needs.’ Hutchmed and AstraZeneca already market savolitinib under the brand name Orpathys in China for a different lung cancer indication. The therapy is undergoing further development for multiple cancer types. Hutchmed shares were down 2.7% at 201.50 pence in London on Monday morning. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
